The worldwide exclusive Flycode® technology enables a whole new ecosystem for antibody profiling and engineering. At its heart are genetically encoded peptide barcodes designed for optimal detection by mass spectrometry. For engineering and screening in vitro and in vivo, each candidate receives a different peptide barcode. This way, we perform multiplex screening on very large pools of antibody candidates in one single experiment. As a result, every candidate within the pool is individually characterised for its unique properties.
The novel Flycode® concept is at the leading edge of antibody engineering technology. Thousands of candidates and even more candidate parameters are measured in parallel in every experiment. Consequently, data collection formolecular properties, multi-specificity and pharmacology at the start of a drug campaign is now possible. This empowers, in turn, in silico analysis with an incredible impact on decision making and novel designs.
Flycode® assays blend in perfectly with classical triaging at any stage of the drug development process. As a novel concept for in vivo screening, it reduces the involvement of life massively and respects 3R values in an exceptional way. At the same time, classical triaging is revolutionised, because Flycodes offer an unprecedented level of parallelisation and throughput. Better data quality at an earlier time combined with in silico design empowers novel antibody engineering and precision medicine development.
It enables identifying the candidate with the best pharmacology, best pharmacokinetic profile and best targeting properties using high-throughput in vivo engineering and in silico analysis.
learn more about flycodes.
We looking forward to your questions.